Harbour BioMed Names Dr Raymond Zheng, Chief Business Officer, To Drive Global Development Initiatives

Harbour BioMed, a global biopharmaceutical company specialising in antibody therapeutics for oncology and immunology, has appointed Dr. Raymond Zheng as its Chief Business Officer (CBO). Based in the United States, Dr. Zheng will oversee global business development and alliance management, reporting directly to Dr. Jingsong Wang, the company’s Founder, Chairman, and CEO.

In his new position, Dr Zheng will focus on enhancing the value of Harbour BioMed’s product portfolio by driving the company’s partnership strategies. He would also play a pivotal role in streamlining resources to manage the global business development activities towards accomplishing the strategic corporate mission of developing transformative medicines to address unmet medical needs.

Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, stated, "Leveraging our proprietary Harbour Mice® fully human antibody platform, we have developed a robust and diverse pipeline with potential first-in-class and best-in-class drug candidates in immuno-oncology, as well as in inflammatory and immunology diseases. Raymond’s deep expertise in business development and strategic insights will be invaluable as we expand our collaborations and accelerate growth in key markets. We are thrilled to welcome him to the Harbour BioMed family and are confident that his leadership will significantly enhance the value of our portfolio."

"I am honoured to join Harbour BioMed and excited to work alongside a talented team committed to developing cutting-edge medicinal products. Harbour Mice® is an industry-leading technology platform that has gained strong recognition worldwide. I look forward to leveraging my experience to foster robust partnerships to drive the Company’s mission and enhance our global impact in the biopharmaceutical industry," commented Dr Raymond Zheng, Chief Business Officer of Harbour BioMed.

Dr. Zheng’s career began in scientific research, including a fellowship in translational oncology at Harvard Medical School before the biopharmaceutical industry. Before joining Harbour BioMed, he founded and served as Chief Scientific Officer of Urica Therapeutics, where he led the early clinical development of an oral therapy for refractory gout, which was later acquired by a venture-backed company for further pivotal development. 

Additionally, he contributed to critical business development initiatives at Fortress Biotech and Agenus, where he negotiated significant partnership deals and managed strategic investments.

Dr. Zheng holds a Ph.D. in Cell and Molecular Biology from the University of California, Riverside, and an MBA in Finance from Rutgers University.